Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Ascendis Pharma A/S American Depositary Shares (ASND)

http://www.ascendispharma.com

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/28/2015

Market Cap

7,897,706,708

Shares Outstanding

57,660,000

Weighted SO

56,594,287

Total Employees

N/A

Upcoming Earnings

09/03/2024

Similar Tickers

APLS --.--%

BGNE --.--%

AKRO --.--%

BPMC --.--%

REPL --.--%

NUVL --.--%

VTYX --.--%

UTHR --.--%

ISEE --.--%

Beta

0.6320

Last Div

0.0000

Range

85.285-161.0

Chg

0.2750

Avg Vol

364559

Mkt Cap

7897706708

Exch

NASDAQ

Country

DK

Phone

45 70 22 22 44

DCF Diff

222.9383

DCF

-80.9733

Div Yield

0.0000

P/S

21.8105

EV Multiple

-21.2105

P/FV

-30.2724

Div Yield %

0.0000

P/E

-14.3754

PEG

-0.3509

Payout

0.0000

Current Ratio

0.8312

Quick Ratio

0.5400

Cash Ratio

0.4008

DSO

76.2020

DIO

1793.8991

Op Cycle

1870.1011

DPO

728.7664

CCC

1141.3347

Gross Margin

0.8561

Op Margin

-1.0972

Pretax Margin

-1.4985

Net Margin

-1.5244

Eff Tax Rate

-0.0173

ROA

-0.6250

ROE

5.1119

ROCE

-102.1797

NI/EBT

1.0173

EBT/EBIT

1.3658

EBIT/Rev

-1.0972

Debt Ratio

0.8337

D/E

-2.8089

LT Debt/Cap

-26.8507

Total Debt/Cap

1.5528

Int Coverage

-3.0225

CF/Debt

-0.6306

Equity Multi

-3.3693

Rec Turnover

4.7899

Pay Turnover

0.5008

Inv Turnover

0.2035

FA Turnover

3.0703

Asset Turnover

0.4100

OCF/Share

-7.4169

FCF/Share

-7.4443

Cash/Share

5.6298

OCF/Sales

-1.2823

FCF/OCF

1.0037

CF Coverage

-0.6306

ST Coverage

-0.9602

CapEx Coverage

-271.1433

Div&CapEx Cov

-271.1433

P/BV

-30.2724

P/B

-30.2724

P/S

21.8105

P/E

-14.3754

P/FCF

-16.9467

P/OCF

-17.0900

P/CF

-17.0900

PEG

-0.3509

P/S

21.8105

EV Multiple

-21.2105

P/FV

-30.2724

DPS

0.0000

Latest Headlines (EST)

Benzinga Sep 22, 21:34 Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? GlobeNewswire Inc. Sep 20, 00:16 Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs GlobeNewswire Inc. Jan 07, 17:45 Ascendis Pharma Introduces Vision 2030 GlobeNewswire Inc. Jan 07, 17:45 Ascendis Pharma Introduces Vision 2030 GlobeNewswire Inc. Jan 07, 17:45 Ascendis Pharma Introduces Vision 2030 GlobeNewswire Inc. Jan 07, 17:45 Ascendis Pharma Introduces Vision 2030 GlobeNewswire Inc. Jan 07, 17:45 Ascendis Pharma Introduces Vision 2030 GlobeNewswire Inc. Jan 07, 17:45 Ascendis Pharma Introduces Vision 2030 GlobeNewswire Inc. Jan 07, 17:45 Ascendis Pharma Introduces Vision 2030 GlobeNewswire Inc. Jan 07, 17:45 Ascendis Pharma Introduces Vision 2030 GlobeNewswire Inc. Jan 07, 17:45 Ascendis Pharma Introduces Vision 2030 GlobeNewswire Inc. Jan 07, 17:45 Ascendis Pharma Introduces Vision 2030 GlobeNewswire Inc. Dec 28, 16:15 Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. Dec 28, 16:15 Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. Dec 20, 08:30 Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide) at 100 µg/kg/week GlobeNewswire Inc. Dec 19, 08:30 TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency GlobeNewswire Inc. Dec 11, 08:30 FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism GlobeNewswire Inc. Nov 29, 04:30 Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan GlobeNewswire Inc. Oct 31, 08:30 Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results and TransCon PTH NDA Resubmission GlobeNewswire Inc. Oct 26, 08:30 Ascendis Presents Updated and New TransCon™ IL-2 β⁄γ Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023

Revenue Product Segmentation